2024-09-01 2025-08-31 false No description of principal activity Acting Office - Tax and Accounts 1.0 13581609 bus:FullAccounts 2024-09-01 2025-08-31 13581609 bus:FRS102 2024-09-01 2025-08-31 13581609 bus:AuditExempt-NoAccountantsReport 2024-09-01 2025-08-31 13581609 bus:SmallCompaniesRegimeForAccounts 2024-09-01 2025-08-31 13581609 bus:PrivateLimitedCompanyLtd 2024-09-01 2025-08-31 13581609 2024-09-01 2025-08-31 13581609 2025-08-31 13581609 bus:RegisteredOffice 2024-09-01 2025-08-31 13581609 core:WithinOneYear 2025-08-31 13581609 core:AfterOneYear 2025-08-31 13581609 2023-09-01 13581609 bus:Director1 2024-09-01 2025-08-31 13581609 bus:Director1 2025-08-31 13581609 bus:Director1 2023-09-01 2024-08-31 13581609 bus:Director2 2024-09-01 2025-08-31 13581609 bus:Director2 2025-08-31 13581609 bus:Director2 2023-09-01 2024-08-31 13581609 bus:CompanySecretary1 2024-09-01 2025-08-31 13581609 bus:LeadAgentIfApplicable 2024-09-01 2025-08-31 13581609 2023-09-01 2024-08-31 13581609 2024-08-31 13581609 core:WithinOneYear 2024-08-31 13581609 core:AfterOneYear 2024-08-31 13581609 bus:EntityAccountantsOrAuditors 2023-09-01 2024-08-31 13581609 core:OfficeEquipment 2024-09-01 2025-08-31 13581609 core:OfficeEquipment 2025-08-31 13581609 core:OfficeEquipment 2024-08-31 13581609 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2025-08-31 13581609 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2024-08-31 13581609 core:CostValuation core:Non-currentFinancialInstruments 2025-08-31 13581609 core:CostValuation core:Non-currentFinancialInstruments 2024-08-31 13581609 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-08-31 13581609 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2025-08-31 13581609 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-08-31 13581609 core:ShareProfitOrLossIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-08-31 13581609 core:ProvisionsForImpairmentInvestments core:Non-currentFinancialInstruments 2025-08-31 13581609 core:ImpairmentReversalProvisionsForImpairmentInvestments core:Non-currentFinancialInstruments 2025-08-31 13581609 core:ForeignExchangeDifferencesIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-08-31 13581609 core:TransfersIntoOrOutInvestmentsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-08-31 13581609 core:TransfersBetweenInvestmentClassesIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-08-31 13581609 core:Non-currentFinancialInstruments 2025-08-31 13581609 core:Non-currentFinancialInstruments 2024-08-31 13581609 core:ShareCapital 2025-08-31 13581609 core:ShareCapital 2024-08-31 13581609 core:RetainedEarningsAccumulatedLosses 2025-08-31 13581609 core:RetainedEarningsAccumulatedLosses 2024-08-31 iso4217:GBP xbrli:shares xbrli:pure

Registered Number: 13581609
England and Wales
Unaudited Financial Statements
for the year ended 31 August 2025
for
BURLINGTON PHARMA LTD

BURLINGTON PHARMA LTD ###### Statement of Financial Position As at 31 August 2025
| Notes | 2025 £ |  | 2024 £
--- | --- | --- | --- | ---
Fixed assets |  |
Tangible fixed assets | 2 | 3,275 |  | 4,093
|  | 3,275 |  | 4,093
Current assets |  |
Debtors | 3 | 41,376 |  | 20,841
Cash at bank and in hand |  | 121,146 |  | 87,997
|  | 162,522 |  | 108,838
Creditors: amount falling due within one year | 4 | (49,442) |  | (55,342)
Net current assets/(liabilities) |  | 113,080 |  | 53,496
Total assets less current liabilities |  | 116,355 |  | 57,589
Net assets/(liabilities) |  | 116,355 |  | 57,589
Capital and reserves |  |
Called up share capital |  | 100 |  | 100
Profit and loss account | 5 | 116,255 |  | 57,489
Shareholders fund |  | 116,355 |  | 57,589
For the year ended 31 August 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. Directors' Responsibilities: The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime of Part 15 of the Companies Act 2006. Signed on behalf of the board of directors:
--------------------------------------------- Cheung Hoe Leong Director |  |
Date approved: 18 May 2026 1

BURLINGTON PHARMA LTD ###### Notes to the Accounts For the year ended 31 Aug 2025
Statutory Information Burlington Pharma Ltd is a private limited company, limited by shares, domiciled in England and Wales, registration number 13581609, registration address Unit 217b Mirror Works 12 Marshgate Lane, London, E15 2NH, England. The presentation currency is £ sterling.
1. | Accounting Policies Basis of accounting The financial statements are prepared under the historical cost convention and in accordance with the FRS 102 Financial Reporting Standard for Smaller Entities (effective January 2016). Turnover Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates and sales taxes. Turnover from the sale of goods is recognised when all of the following conditions are satisfied: • the company has transferred the significant risks and rewards of ownership to the buyer; • the company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold; • the amount of revenue can be measured reliably; • it is probable that the company will receive the consideration due under the transaction; and • the costs incurred or to be incurred in respect of the transaction can be measured reliably. Rendering of services Turnover from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied: • the amount of revenue can be measured reliably; • it is probable that the Company will receive the consideration due under the contract; • the stage of completion of the contract at the end of the reporting period can be measured reliably; and • the costs incurred and the costs to complete the contract can be measured reliably. Where a contract has only been partially completed at the Balance Sheet date turnover represents the fair value of the service provided to date based on the stage of completion of the contract activity at the Balance Sheet date. Where payments are received from customers in advance of services provided, the amounts are recorded as deferred income and included as part of creditors due within one year. Website cost Planning and operating costs for the company's website are charged to the profit and loss account as incurred. Taxation Current tax, including UK corporation tax and foreign tax, is provided at amounts expected to be paid (or recovered) using the tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date. Dividends Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting. Proposed dividends are only included as liabilities in the financial statements when their payment has been approved by the shareholders prior to the balance sheet date. Tangible fixed assets Tangible fixed assets, other than freehold land, are stated at historical cost or valuation less depreciation and any provision for impairment. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis: Employee benefits Short-term employee benefits are recognised as an expense in the period in which they are incurred. Long-term employee benefits are measured at the present value of the benefit obligation at the reporting date. Termination benefits are recognised as an expense when the Company is demonstrably committed to terminate the employment of an employee or to provide termination benefits. Finance costs Finance costs are charged to the Profit and Loss Account over the term of the debt using the effective interest method so the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument. Cash and cash equivalents Cash and cash equivalents are highly liquid investments and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year. Trade and other creditors Short-term creditors are measured at the transaction price. The other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, unless the effect of discounting would be immaterial, in which case they are stated at cost. Equity instruments Equity instruments issued by the Company are recorded at the fair value of cash or other resources received or receivable, net of direct issue costs. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the Company. Defined contribution schemes The obligations for contributions to defined contribution scheme are recognised as an expense to the Profit and Loss Account in respect of pension costs and other post-retirement benefits, in the period they are incurred. The assets of the scheme are held separately from those of the company in an independently administered fund. Differences between contributions payable in the financial year and contributions actually paid are shown as either accruals or prepayments in the Balance Sheet.
2. | Tangible fixed assets
Cost or Valuation |  | Office Equipment |  | Total
|  | £ |  | £
At 01 September 2024 |  | 5,941 |  | 5,941
Additions |  | - |  | -
At 31 August 2025 |  | 5,941 |  | 5,941
Depreciation
At 01 September 2024 |  | 1,848 |  | 1,848
Charge for year |  | 818 |  | 818
At 31 August 2025 |  | 2,666 |  | 2,666
Net book values
Closing balance as at 31 August 2025 |  | 3,275 |  | 3,275
Opening balance as at 01 September 2024 |  | 4,093 |  | 4,093
3. | Debtors: amounts falling due within one year
| 2025 £ |  | 2024 £
--- | --- | --- | ---
VAT | 41,376 |  | 20,841
| 41,376 |  | 20,841
4. | Creditors: amount falling due within one year
| 2025 £ |  | 2024 £
--- | --- | --- | ---
Accrued expenses | 399 |  | 1,000
Other creditors | 9,148 |  | 9,147
Pension Payable | 122 |  | 122
Directors' current accounts | 22,820 |  | 31,781
Corporation tax | 16,622 |  | 12,520
Social security & other tax | 331 |  | 772
| 49,442 |  | 55,342
5. | Profit and loss account
| 2025 £
--- | ---
Balance at 01 September 2024 | 57,489
Profit for the year | 58,766
Balance at 31 August 2025 | 116,255
6. | Average number of employees Average number of employees during the year were 2 (2024: 2).
2